- Home
- FGB vs SPRO Comparison
FGB vs SPRO Comparison
Compare FGB & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- SPRO
- Stock Information
- Founded
- FGB 2007
- SPRO 2013
- Country
- FGB United States
- SPRO United States
- Employees
- FGB N/A
- SPRO N/A
- Industry
- FGB Finance/Investors Services
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- FGB Finance
- SPRO Health Care
- Exchange
- FGB Nasdaq
- SPRO Nasdaq
- Market Cap
- FGB 61.1M
- SPRO 62.7M
- IPO Year
- FGB N/A
- SPRO 2017
- Fundamental
- Price
- FGB $4.22
- SPRO $1.17
- Analyst Decision
- FGB
- SPRO Buy
- Analyst Count
- FGB 0
- SPRO 3
- Target Price
- FGB N/A
- SPRO $5.00
- AVG Volume (30 Days)
- FGB 53.0K
- SPRO 470.6K
- Earning Date
- FGB 01-01-0001
- SPRO 11-14-2024
- Dividend Yield
- FGB 8.92%
- SPRO N/A
- EPS Growth
- FGB N/A
- SPRO N/A
- EPS
- FGB N/A
- SPRO 0.06
- Revenue
- FGB N/A
- SPRO $106,455,000.00
- Revenue This Year
- FGB N/A
- SPRO N/A
- Revenue Next Year
- FGB N/A
- SPRO N/A
- P/E Ratio
- FGB N/A
- SPRO $17.92
- Revenue Growth
- FGB N/A
- SPRO 37.01
- 52 Week Low
- FGB $2.85
- SPRO $1.01
- 52 Week High
- FGB $3.74
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- FGB 67.50
- SPRO 41.49
- Support Level
- FGB $4.14
- SPRO $1.28
- Resistance Level
- FGB $4.21
- SPRO $1.22
- Average True Range (ATR)
- FGB 0.05
- SPRO 0.07
- MACD
- FGB 0.01
- SPRO -0.01
- Stochastic Oscillator
- FGB 76.00
- SPRO 32.73
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.